Skip to main content
. 2017 Feb 24;7(2):e013899. doi: 10.1136/bmjopen-2016-013899

Figure 1.

Figure 1

Patients exposed to treatment, by BMI category and drug class, during (A) the 1-year observation period and (B) the period up to data cut-off. (A) *p<0.001 vs overweight and obese subjects; †p<0.001 vs obese subjects. (B) *p<0.001 vs overweight and obese subjects; †p<0.001 vs obese subjects. BMI, body mass index.